68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients
| Autor: | Olaf Prante, Michael Uder, Christian Schmidkonz, Philipp Ritt, Peter J. Goebell, Tobias Bäuerle, Michael Cordes, Torsten Kuwert, Theresa Ida Goetz, Bernd Wullich |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Biochemical recurrence
Male Time Factors Bone density Computed tomography Bone Neoplasms Gallium Radioisotopes urologic and male genital diseases 030218 nuclear medicine & medical imaging 68Ga-PSMA-11 Lesion 03 medical and health sciences Prostate cancer 0302 clinical medicine Recurrence Positron Emission Tomography Computed Tomography medicine Humans Radiology Nuclear Medicine and imaging Edetic Acid Gallium Isotopes Aged Aged 80 and over PET-CT medicine.diagnostic_test business.industry Prostatic Neoplasms General Medicine Middle Aged medicine.disease Treatment Outcome 030220 oncology & carcinogenesis Tomography medicine.symptom Neoplasm Grading business Nuclear medicine Oligopeptides |
| Zdroj: | Annals of nuclear medicine. 33(10) |
| ISSN: | 1864-6433 |
| Popis: | To evaluate the role of 68Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC). A total of 177 men with biochemical recurrence of prostate cancer suffering from bone metastases underwent PET/CT with [68Ga] Ga-PSMA-HBED-CC (68Ga-PSMA-11). To calculate 68Ga-PSMA-11 PET quantitative volumetric tumor parameters including whole-body total-lesion PSMA (TL-PSMA), whole-body PSMA-tumor volume (PSMA-TV), as well as the established maximum standard uptake values (SUVmax) and mean standard uptake values (SUVmean), all 443 68Ga-PSMA-11-positive bone lesions in the field of view were assessed quantitatively. Quantitative volumetric tumor parameters were correlated with CT-derived volume and bone density measurements of metastatic bone lesions, serum prostate-specific antigen (PSA) levels, and Gleason Scores. In the 20 patients suffering from bone metastases who underwent 68Ga-PSMA-11 PET/CT before and after therapy, CT-derived volume and bone density measurements of metastatic lesions were compared to biochemical response determined by serum-PSA levels. In 177 patients, a total of 443 68Ga-PSMA-11 PET-positive bone lesions were detected. Of these, 50 lesions (11%) were only detectable on PET but not on conventional CT. PET-positive/CT-negative bone metastases demonstrated a significantly lower PSMA uptake compared to PET-positive/CT-positive bone lesions (p 7 compared to those with Gleason Scores ≤ 7. In the linear regression analysis, an association was determined between SUVmean, Gleason Scores, lesion classification, and serum-PSA levels but not for CT-derived bone density measurements. No significant correlation could be found between changes of bone density and CT-derived volume measurements of metastatic bone lesions and changes of serum-PSA levels (p > 0.05) before and after therapy, while a highly significant correlation was observed for changes of PSMA-TV, TL-PSMA, and serum-PSA levels (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink